60 Degrees Pharmaceuticals, Inc. (SXTP) Balance Sheet

NASDAQ: SXTPAssets, liabilities, debt and equity over 6 years.

SXTP balance sheet, 2025

December 31, 2025 · U.S. dollars

$5.4M assets = $2.0M liabilities + $3.4M equity

What it owns$5.4MCash & ST investments: $2.8M (51.3%)Cash & ST investments$2.8M · 51%Receivables: $509,644 (9.5%)Receivables $509,644Inventory: $656,924 (12.2%)Inventory$656,924 · 12%Other current: $978,131 (18.2%)Other current$978,131 · 18%PP&E: $246,365 (4.6%)Goodwill & intangibles: $224,361 (4.2%)=How it is financed$5.4MCurrent liabilities: $1.8M (34.3%)Current liabilities$1.8M · 34%Long-term debt: $144,003 (2.7%)Shareholders’ equity: $3.4M (63.0%)Shareholders’ equity$3.4M · 63%

Both columns are drawn to the same scale: what SXTP owns equals what it owes plus shareholders’ equity. Hover a block for its value.

SXTP financial health

Current ratio2.66
Comfortable · current assets cover current liabilities 2.66×
Debt / equity0.04
Low leverage · $0.04 of debt for each $1 of equity
Equity / assets64.5%
Equity-funded · of assets funded by shareholders
Cash / debt1,800.5%
Cash covers debt · cash & short-term investments vs total debt
Goodwill & intangibles4.2%
Mostly tangible · of total assets

Descriptive bands, not a rating. Fiscal 2025.

SXTP balance sheet trends, 2020–2025

60 Degrees Pharmaceuticals, Inc. balance sheet trends
MetricTrendThenLatestChange
Total assets$2.6M2020$5.4M2025+15.5%/yr
Total liabilities$20.7M2020$2.0M2025−37.4%/yr
Shareholders’ equity−$17.5M2020$3.5M2025—
Cash & short-term investments$191,7022020$2.8M2025+70.4%/yr
Total debt$15.9M2020$152,7752025−60.5%/yr
Net cash (debt)−$15.7M2020$2.6M2025+$18.3M
Working capital$1.0M2020$3.1M2025+$2.0M
Current ratio1.7020202.662025+0.95
Debt / equity0.0420230.042025+0.01

Change is the average annual growth (CAGR) or the difference between the first and latest year.

SXTP assets

Cash & ST investmentsReceivablesInventoryOther currentPP&EGoodwill & intangiblesLT investmentsOther non-current

SXTP liabilities and equity

Current liabilitiesLong-term debtOther long-term liabilitiesEquity

SXTP debt vs cash

Total debtCash & ST investmentsNet cash (debt)

Debt includes short- and long-term borrowings and, where reported, lease obligations.

SXTP balance sheet

60 Degrees Pharmaceuticals, Inc. annual balance sheet
202520242023202220212020
Assets
Cash & short-term investments$2.8M$3.4M$2.1M$264,865$115,399$191,702
Cash & equivalents$1.5M$1.7M$2.1M$264,865$115,399$191,702
Short-term investments$1.2M$1.7M————
Receivables$509,644$486,748$231,332$45,965$146,362$859,425
Inventory$656,924$442,764$466,169$518,578$689,042$1.0M
Other current assets$978,131$1.1M$4.4M$269,596$225,869$352,164
Total current assets$4.9M$5.4M$7.2M$1.1M$1.2M$2.4M
Property, plant & equipment (net)$246,365$149,808$71,278$33,947$107,615$73,408
Goodwill & intangible assets$224,361$157,084$227,258$164,255$109,240$80,226
Long-term investments$0$0$0$0$0$0
Other non-current assets$0$66,176$242,647$0$0$9,549
Total assets$5.4M$5.8M$7.8M$1.3M$1.4M$2.6M
Liabilities
Accounts payable$1.5M$1.0M$506,206$758,668$588,678$1.4M
Short-term debt$8,772$8,772$22,422$21.1M$140,683$53,306
Deferred revenue———$325,000−$3,133−$53,306
Total current liabilities$1.8M$1.7M$2.8M$23.9M$635,473$1.4M
Long-term debt$144,003$147,119$150,251$1.3M$18.7M$15.9M
Lease obligations—$0$13,650$13,000$59,795$0
Other long-term liabilities$0$0$0$255,000$167,743$3.3M
Total liabilities$2.0M$1.8M$3.0M$25.4M$19.5M$20.7M
Shareholders' equity
Common stock & paid-in capital$116$57$10$239$5.0M$799,700
Retained earnings (deficit)−$47.9M−$40.5M−$32.6M−$28.8M−$22.6M−$18.4M
Accumulated other comprehensive income$142,598$135,471$135,560$73,708$75,835$80,454
Minority interest−$83,761−$80,594−$72,038−$572,320——
Total shareholders' equity$3.5M$4.0M$4.9M−$23.6M−$17.6M−$17.5M
Key figures
Total debt$152,775$155,891$172,673$22.4M$18.8M$15.9M
Net cash (debt)$2.6M$3.2M$2.0M−$22.2M−$18.7M−$15.7M
Working capital$3.1M$3.7M$4.4M−$22.8M$541,199$1.0M
Tangible book value$3.2M$3.9M$4.6M−$23.7M−$17.7M−$17.6M
Current ratio2.663.252.550.051.851.70
Quick ratio1.772.340.840.010.410.73
Debt / equity0.040.040.04———
Equity / assets64.5%70.1%62.6%−1,817.5%−1,261.4%−671.6%

Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed March 30, 2026); data from EODHD.

SXTP financial position

At the end of fiscal 2025 (December 31, 2025), 60 Degrees Pharmaceuticals had total assets of $5.4 million (down 6.8% from a year earlier), total liabilities of $2.0 million and shareholders' equity of $3.5 million. It held $2.8 million in cash and short-term investments against $0.2 million of debt, a net cash position of $2.6 million. Its current ratio was 2.66. In the latest quarter (ended June 30, 2026) total assets were $4.3 million and equity $2.6 million.

Related: SXTP income statement, SXTP cash flow statement, SXTP key metrics. See the SXTP stock overview for the latest quote and news.

SXTP balance sheet FAQ

What are 60 Degrees Pharmaceuticals's total assets?

60 Degrees Pharmaceuticals reported total assets of $5.4 million at the end of fiscal 2025 (December 31, 2025), compared with $5.8 million a year earlier.

How much debt does 60 Degrees Pharmaceuticals have?

60 Degrees Pharmaceuticals had $0.2 million of total debt at the end of fiscal 2025, including short-term borrowings. Its debt-to-equity ratio was 0.04.

How much cash does 60 Degrees Pharmaceuticals have?

60 Degrees Pharmaceuticals held $2.8 million in cash and short-term investments at the end of fiscal 2025; with $0.2 million of debt that is net cash of $2.6 million.

What is 60 Degrees Pharmaceuticals's book value?

60 Degrees Pharmaceuticals's shareholders' equity (book value) was $3.5 million at the end of fiscal 2025.

What is 60 Degrees Pharmaceuticals's current ratio?

60 Degrees Pharmaceuticals had current assets of $4.9 million and current liabilities of $1.8 million, a current ratio of 2.66 (it can cover its short-term obligations).

How much goodwill does 60 Degrees Pharmaceuticals have?

60 Degrees Pharmaceuticals carried $0.2 million of goodwill and intangible assets, 4.2% of total assets, at the end of fiscal 2025.

Biotechnology: balance sheet